Fosun International

BioNTech to Report First Quarter 2021 Financial Results and Operational Update on May 10, 2021

Tuesday, May 4, 2021 - 12:02pm

The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals.

Key Points: 
  • The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals.
  • Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules.
  • Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline.
  • BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer.\n'

Baozun Announces Strategic Alliance with Fosun Fashion Group to Capture Potential of Luxury Sector

Wednesday, April 28, 2021 - 11:00am

Baozun will become a minority shareholder in FFG, along with other strategic investors and seasoned industry players, by participating in FFG\xe2\x80\x99s financing, in which Fosun will serve as the lead investor.

Key Points: 
  • Baozun will become a minority shareholder in FFG, along with other strategic investors and seasoned industry players, by participating in FFG\xe2\x80\x99s financing, in which Fosun will serve as the lead investor.
  • Vincent Qiu, Chairman and Chief Executive Officer of Baozun commented, \xe2\x80\x9cWe are pleased to have established a strategic alliance with Fosun Fashion Group and are excited about the opportunities ahead.
  • Fosun Fashion Group not only brings us an extended portfolio of luxury brand partners, but also gives us deeper insight into the global luxury sector.
  • The alliance helps to extend our value chain in the luxury segment, taking advantage of Fosun Fashion Group\xe2\x80\x99s strong understanding of the brands and track record in brand building.

Fosun Fashion Group Forms Strategic Alliance with Baozun, Activation and Other Industry Partners to Capture Untapped Potential in Luxury Sector

Wednesday, April 28, 2021 - 11:00am

The consortium aims to serve the ever-changing global luxury market by developing a top-tier ecosystem to promote additional operational value in China.

Key Points: 
  • The consortium aims to serve the ever-changing global luxury market by developing a top-tier ecosystem to promote additional operational value in China.
  • Vincent Qiu, Chairman and Chief Executive Officer of Baozun commented, "We are pleased to have established a strategic alliance with Fosun Fashion Group and are excited about the opportunities ahead.
  • Fosun Fashion Group not only brings us an extended portfolio of luxury brand partners, but also gives us deeper insight into the global luxury sector.
  • Steve Lau Kam Yiu, Joint-chairman and Chief Executive Officer of Activation, said: "We are truly excited to become part of this strategic alliance in the luxury fashion arena.

Revance Announces First Patient Enrolled for DaxibotulinumtoxinA in Glabellar Lines and Cervical Dystonia in China by Fosun Pharma

Tuesday, April 27, 2021 - 1:00pm

Under the license agreement, Fosun Pharma Industrial is responsible for conducting necessary clinical studies, marketing and sales in the Territory, while Revance is responsible for manufacturing drug substance and finished drug product for Fosun Pharma Industrial\xe2\x80\x99s clinical and commercial activities.

Key Points: 
  • Under the license agreement, Fosun Pharma Industrial is responsible for conducting necessary clinical studies, marketing and sales in the Territory, while Revance is responsible for manufacturing drug substance and finished drug product for Fosun Pharma Industrial\xe2\x80\x99s clinical and commercial activities.
  • DaxibotulinumtoxinA for Injection combines a proprietary stabilizing peptide excipient with a highly purified botulinum toxin that does not contain human or animal-based components.
  • Revance has successfully completed a Phase 3 program for DaxibotulinumtoxinA for Injection in glabellar (frown) lines and is pursuing U.S. regulatory approval.
  • Revance is also evaluating DaxibotulinumtoxinA for Injection in the full upper face, including glabellar lines, forehead lines and crow\'s feet, as well as in two therapeutic indications - cervical dystonia and adult upper limb spasticity.

Citrine Medicine and Sinopharm Group Announce Strategic Partnership to Broaden and Accelerate Access to Rare Disease Drugs in China

Monday, April 19, 2021 - 2:00pm

b'BOSTON and SHANGHAI, April 19, 2021 /PRNewswire/ --Citrine Medicine, aChina-based rare disease therapeutics company, and Sinopharm Group, a Chinese pharmaceutical company, today announced a strategic partnership to accelerate the commercialization of rare disease drugs in China.

Key Points: 
  • b'BOSTON and SHANGHAI, April 19, 2021 /PRNewswire/ --Citrine Medicine, aChina-based rare disease therapeutics company, and Sinopharm Group, a Chinese pharmaceutical company, today announced a strategic partnership to accelerate the commercialization of rare disease drugs in China.
  • "As a leading biopharmaceutical company in China, Citrine Medicine is working to introduce multiple innovative drugs to serve patients with rare diseases.
  • "\n"This new partnership with Sinopharm Group brings us closer to our vision of creating the very first rare disease ecosystem for patients in China," saidMelissa Bradford-Klug, President and Chief Business Officer of Citrine.
  • Our mission is to build the first rare disease ecosystem in China and in doing so, enable people with rare diseases to live more normal lives.

UTime Limited Announces Pricing of Initial Public Offering

Tuesday, April 6, 2021 - 8:01am

NEW YORK, April 6, 2021 /PRNewswire/ --UTime Limited ("UTime" or the "Company") (Nasdaq: UTME), a mobile device manufacturing company committed to providing cost effective products and solutions to consumers globally, today announced the pricing of its initial public offering of 3,750,000 shares of its ordinary shares at a price of US$4.00 per share to the public for a total of US$15 million of gross proceeds to UTime.

Key Points: 
  • NEW YORK, April 6, 2021 /PRNewswire/ --UTime Limited ("UTime" or the "Company") (Nasdaq: UTME), a mobile device manufacturing company committed to providing cost effective products and solutions to consumers globally, today announced the pricing of its initial public offering of 3,750,000 shares of its ordinary shares at a price of US$4.00 per share to the public for a total of US$15 million of gross proceeds to UTime.
  • The offering is expected to close on April 8, 2021, subject to customary closing conditions.
  • Boustead Securities, LLC ("Boustead"), acted as the lead underwriter for the offering, with Brilliant Norton Securities Company Limited and Fosun Hani Securities Limited serving as co-underwriters.
  • In addition, a copy of the final prospectus relating to the offering may be obtained via the SEC's website at www.sec.gov .

First High-School Education Group Announces Closing of Initial Public Offering and Concurrent Private Placement

Friday, March 19, 2021 - 11:00am

The initial public offering and the concurrent private placement raised $79,500,000 in total, in which $54,500,000 was raised by the Company, and $25,000,000 was raised by Longwater Topco B.V., the selling shareholder in the offering, before deducting underwriting discounts and commissions as well as other offering expenses.

Key Points: 
  • The initial public offering and the concurrent private placement raised $79,500,000 in total, in which $54,500,000 was raised by the Company, and $25,000,000 was raised by Longwater Topco B.V., the selling shareholder in the offering, before deducting underwriting discounts and commissions as well as other offering expenses.
  • AMTD Global Markets Limited, Maxim Group LLC, Boustead Securities, LLC, Futu Inc., US Tiger Securities, Inc., and Fosun Hani Securities Limited are acting as Co-managers of the offering.
  • A registration statement relating to the shares being sold in this offering was declared effective by the U.S. Securities and Exchange Commission.
  • First High-School Education Group is the largest operator of private high schools in Western China and the third largest operator in China[2].

Mevion Joins Partnership to Open the First Children’s Proton Center in China

Thursday, March 11, 2021 - 12:00pm

Mevion Medical Systems announced today that it has signed a partnership agreement with Childrens Hospital of Fudan University in Shanghai and Shanghai Fosun Healthcare (Group) Co., Ltd. to establish the first pediatric proton therapy center in China.

Key Points: 
  • Mevion Medical Systems announced today that it has signed a partnership agreement with Childrens Hospital of Fudan University in Shanghai and Shanghai Fosun Healthcare (Group) Co., Ltd. to establish the first pediatric proton therapy center in China.
  • However, the lack of operating proton centers and specialized medical professionals has significantly limited Chinese pediatric patients access to proton therapy.
  • The new proton therapy center will be located at StarKids Childrens Hospital Shanghai, on the New Hong Qiao campus of Childrens Hospital of Fudan University.
  • Mevions flagship product, the MEVION S250i Proton Therapy System with HYPERSCAN pencil beam scanning, is the worlds smallest proton therapy system that eliminates the obstacles of size, complexity, and cost that exists with other proton therapy systems.

First High-School Education Group Announces Pricing of Initial Public Offering

Thursday, March 11, 2021 - 9:16am

The Company expects to offer 5,000,000 ADSs and Longwater Topco B.V. (the "Selling Shareholder") expects to offer 2,500,000 ADSs in aggregate in the Offering.

Key Points: 
  • The Company expects to offer 5,000,000 ADSs and Longwater Topco B.V. (the "Selling Shareholder") expects to offer 2,500,000 ADSs in aggregate in the Offering.
  • The Offering is expected to close on March 15, 2021, subject to the satisfaction of customary closing conditions.
  • AMTD Global Markets Limited, Maxim Group LLC, Boustead Securities, LLC, Futu Inc., US Tiger Securities, Inc., and Fosun Hani Securities Limited are acting as Co-managers of the offering.
  • First High-School Education Group is the largest operator of private high schools in Western China and the third largest operator in China[2].

Polyphor Announces Financial Results for the Full-Year 2020

Friday, March 5, 2021 - 6:15am

Polyphor achieved significant progress in 2020 despite the unprecedented challenges of the COVID-19 pandemic.

Key Points: 
  • Polyphor achieved significant progress in 2020 despite the unprecedented challenges of the COVID-19 pandemic.
  • In August 2020, Polyphor entered into an exclusive licensing agreement for balixafortide in China with Fosun Pharma, one of the leading Chinese healthcare companies with a global footprint.
  • In December 2020, Polyphor extended an earlier funding agreement from 2019 with CARB-X to support the development of the companys novel OMPTA-BamA program.
  • Polyphor started 2020 with a solid financial position, a renewed strategy and organizational restructuring.